Furthermore, COX6C upregulation was associated with poor overall survival (OS) in basal‐like breast cancer, while poor OS and distant metastasis‐free survival (DMFS) in HER2‐positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.